Clinical Research Directory
Browse clinical research sites, groups, and studies.
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Sponsor: Oruka Therapeutics, Inc.
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Official title: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-08-20
Completion Date
2029-09
Last Updated
2026-08-31
Healthy Volunteers
No
Conditions
Interventions
ORKA-002
ORKA-002 administered by subcutaneous (SC) injection
Placebo
Placebo administered by subcutaneous (SC) injection
Locations (2)
Oruka Therapeutics Investigative Site
Chapel Hill, North Carolina, United States
Oruka Therapeutics Investigative Site
Dallas, Texas, United States